Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM2 | P50570 | 12/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | TRIM58 | Q8NG06 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13329945 | 0.90 | DNM2 (0.81) | DNM2ALDH1A1LMNATP53TSHR | |
| SCHEMBL13329946 | 0.90 | DNM2 (0.81) | DNM2ALDH1A1LMNATP53TSHR | |
| SCHEMBL1194281 | 0.89 | DNM2 (0.78) | DNM2ALDH1A1LMNATP53TSHR | |
| SCHEMBL13329951 | 0.87 | DNM2 (0.77) | DNM2ALDH1A1LMNATP53TSHR | |
| SCHEMBL16608857 | 0.84 | ALDH1A1 (0.73) | DNM2ALDH1A1LMNATP53TSHR | |
| SCHEMBL15360223 | 0.80 | DNM2 (0.66) | DNM2ALDH1A1LMNATP53TSHR | |
| SCHEMBL11462337 | 0.79 | DNM2 (0.63) | DNM2MAPK1 | |
| SCHEMBL16608745 | 0.77 | DNM2 (0.61) | DNM2ALDH1A1LMNATP53TSHR | |
| SCHEMBL13329923 | 0.77 | DNM2 (0.63) | DNM2ALDH1A1LMNATP53TSHR | |
| SCHEMBL13329917 | 0.77 | DNM2 (0.63) | DNM2ALDH1A1LMNATP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142547-A1 | COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURRENCE OF A CORONAVIRIDAE INFECTION | ABIVAX (FR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142547-A1 | COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURRENCE OF A CORONAVIRIDAE INFECTION | ACE, ACE2, SARS1 | DNM2 1392/4885ALDH1A1 1057/4885LMNA 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.